Cargando…

Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics

Diabetic kidney disease (DKD) affects an estimated 20–40% of type 2 diabetes patients and is among the most prevalent microvascular complications in this patient population, contributing to high morbidity and mortality rates. Currently, changes in albuminuria status are thought to be a primary indic...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Lan, Han, Yuanyuan, Tu, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842482/
https://www.ncbi.nlm.nih.gov/pubmed/36760602
http://dx.doi.org/10.2147/DMSO.S392888
_version_ 1784870135807344640
author Wei, Lan
Han, Yuanyuan
Tu, Chao
author_facet Wei, Lan
Han, Yuanyuan
Tu, Chao
author_sort Wei, Lan
collection PubMed
description Diabetic kidney disease (DKD) affects an estimated 20–40% of type 2 diabetes patients and is among the most prevalent microvascular complications in this patient population, contributing to high morbidity and mortality rates. Currently, changes in albuminuria status are thought to be a primary indicator of the onset or progression of DKD, yet progressive nephropathy and renal impairment can occur in certain diabetic individuals who exhibit normal urinary albumin levels, emphasizing the lack of sensitivity and specificity associated with the use of albuminuria as a biomarker for detecting diabetic kidney disease and predicting DKD risk. According to the study, a non-invasive method for early detection or prediction of DKD may involve combining proteomic analytical techniques such second generation sequencing, mass spectrometry, two-dimensional gel electrophoresis, and other advanced system biology algorithms. Another category of proteins of relevance may now be provided by renal tissue biomarkers. The establishment of reliable proteomic biomarkers of DKD represents a novel approach to improving the diagnosis, prognostic evaluation, and treatment of affected patients. In the present review, a series of protein biomarkers that have been characterized to date are discussed, offering a theoretical foundation for future efforts to aid patients suffering from this debilitating microvascular complication.
format Online
Article
Text
id pubmed-9842482
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-98424822023-02-08 Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics Wei, Lan Han, Yuanyuan Tu, Chao Diabetes Metab Syndr Obes Review Diabetic kidney disease (DKD) affects an estimated 20–40% of type 2 diabetes patients and is among the most prevalent microvascular complications in this patient population, contributing to high morbidity and mortality rates. Currently, changes in albuminuria status are thought to be a primary indicator of the onset or progression of DKD, yet progressive nephropathy and renal impairment can occur in certain diabetic individuals who exhibit normal urinary albumin levels, emphasizing the lack of sensitivity and specificity associated with the use of albuminuria as a biomarker for detecting diabetic kidney disease and predicting DKD risk. According to the study, a non-invasive method for early detection or prediction of DKD may involve combining proteomic analytical techniques such second generation sequencing, mass spectrometry, two-dimensional gel electrophoresis, and other advanced system biology algorithms. Another category of proteins of relevance may now be provided by renal tissue biomarkers. The establishment of reliable proteomic biomarkers of DKD represents a novel approach to improving the diagnosis, prognostic evaluation, and treatment of affected patients. In the present review, a series of protein biomarkers that have been characterized to date are discussed, offering a theoretical foundation for future efforts to aid patients suffering from this debilitating microvascular complication. Dove 2023-01-12 /pmc/articles/PMC9842482/ /pubmed/36760602 http://dx.doi.org/10.2147/DMSO.S392888 Text en © 2023 Wei et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Wei, Lan
Han, Yuanyuan
Tu, Chao
Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics
title Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics
title_full Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics
title_fullStr Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics
title_full_unstemmed Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics
title_short Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics
title_sort molecular pathways of diabetic kidney disease inferred from proteomics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842482/
https://www.ncbi.nlm.nih.gov/pubmed/36760602
http://dx.doi.org/10.2147/DMSO.S392888
work_keys_str_mv AT weilan molecularpathwaysofdiabetickidneydiseaseinferredfromproteomics
AT hanyuanyuan molecularpathwaysofdiabetickidneydiseaseinferredfromproteomics
AT tuchao molecularpathwaysofdiabetickidneydiseaseinferredfromproteomics